One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions


  • M. Calderón,

    Corresponding author
    • Imperial College London, National Heart and Lung Institute, London, UK
    Search for more papers by this author
  • V. Cardona,

    1. University Hospital of Vall d'Hebron, Barcelona, Spain
    Search for more papers by this author
  • P. Demoly,

    1. University Hospital of Montpellier, Montpellier, France
    Search for more papers by this author
  • on behalf of the EAACI 100 Years of Immunotherapy Experts Panel

    Search for more papers by this author
    • EAACI Experts Panel members: Giovanni Passalacqua, Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine, Genoa, Italy; Jörg Kleine-Tebbe, Allergy & Asthma Center Westend, Berlin, Germany; Erkka Valovirta, Suomen Terveystalo Allergy Clinic, Turku, Finland; Stephen R Durham, Imperial College London, National Heart and Lung Institute, London, UK; Ronald Dahl, Aarhus University, Denmark; Hans-Jorgen Malling, Allergy Unit, University Hospital, Copenhagen, Denmark; Antony Frew, University of Southampton; Montserrat Fernandez-Rivas, Hospital Clinico San Carlos, IdISSC, Madrid, Spain; Rudolf Valenta, Christian Doppler Laboratory for Allergy Research, Medical University of Vienna, Austria; Ulrich Wahn, Charité University of Medicine, Berlin, Germany; Albrecht Bufe, Ruhr University, Bochum, Germany.

  • Edited by: Thomas Bieber


Moisés Calderón, Imperial College London, National Heart and Lung Institute, London, UK.

Tel.: +44 20 73518024

Fax: +44 20 73497780



Allergen immunotherapy was introduced by Leonard Noon 100 years ago and is the only disease-modifying treatment for allergic individuals. Improved understanding of immunology has taught us a great deal about the underlying mechanisms involved in allergen immunotherapy; however, despite these developments, a number of important questions remain unanswered. Several of these questions relate to the practice of allergen immunotherapy in the clinic, such as: Is it possible to unify units of allergen potency? Which treatment schedules are best? Is allergen immunotherapy effective in all patient groups? Is there a dose–response relationship for efficacy and safety?, and Is there evidence for long-term effects following allergen immunotherapy? Others are related to new developments, such as new indications, or developments in the production of allergens. On the centenary of Noon's discovery, European experts in the field of immunotherapy met in Geneva under the aegis of the EAACI to discuss these controversial issues. This study presents outcomes and conclusions from these discussions.